GIP and GLP-1 receptor co-agonist
Tirzepatide 0.5 mg injection once weekly
TIRZ_SC_0p5MG_QW
Related
- All doses pooled: Tirzepatide injection
- Tirzepatide 1 mg subcutaneous once weekly
- Tirzepatide 5 mg subcutaneous once weekly
- Tirzepatide 10 mg subcutaneous once weekly
- Tirzepatide 15 mg subcutaneous once weekly
- Tirzepatide maximum tolerated dose injection once weekly
- Tirzepatide subcutaneous once weekly, maximum tolerated dose: 10 or 15 mg
- Tirzepatide 0.25 mg injection
- Tirzepatide 4.5 mg injection once weekly
- Tirzepatide 0.5 mg injection
- Tirzepatide 1 mg injection
- Tirzepatide 2.5 mg injection
- Tirzepatide 5 mg injection
- Tirzepatide 8 mg injection
- Tirzepatide 1.5 mg injection once weekly
- Tirzepatide 12 mg injection once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.64 (0.01 to 48.89) | 0.43 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.23 (0.00 to 4.95) | 0.79 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.38 (0.00 to 13.52) | 0.66 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.65 (0.05 to 3.50) | 0.79 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.58 (0.05 to 3.15) | 0.80 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.66 (0.06 to 3.55) | 0.74 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.36 (0.00 to 8.64) | 0.72 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.93 (0.05 to 16.45) | 0.46 |